We established the molecular basis for pyruvate kinase (PK) deficiency in a white male patient with severe nonspherocytic hemolytic anemia. The paternal allele exhibited the common PKLR cDNA sequence (c.) 1529G>A mutation, known to be associated with PK deficiency. On the maternal allele, 3 in cis mutations were identified in the erythroid-specific promoter region of the gene: one deletion of thymine ؊248 and 2 single nucleotide substitutions, nucleotide (nt) ؊324T>A and nt ؊83G>C. Analysis of the patient's RNA demonstrated the presence of only the 1529A allele, indicating severely reduced transcription from the allele linked to the mutated promoter region. Transfection of promoter constructs into erythroleukemic K562 cells showed that the most upstream ؊324T>A and ؊248delT mutations were nonfunctional polymorphisms. In contrast, the ؊83G>C mutation strongly reduced promoter activity. Sitedirected mutagenesis of the promoter region revealed the presence of a putative regulatory element (PKR-RE1) whose core binding motif, CTCTG, is located between nt ؊87 and nt ؊83. Electrophoretic mobility shift assay using K562 nuclear extracts indicated binding of an as-yetunidentified trans-acting factor. This novel element mediates the effects of factors necessary for regulation of pyruvate kinase gene expression during red cell differentiation and maturation. (Blood.
Introduction
Pyruvate kinase (PK) catalyzes the final step of glycolysis in which phosphoenolpyruvate is converted to pyruvate with the concomitant generation of adenosine triphosphate (ATP). Pyruvate kinase deficiency is the most common cause of nonspherocytic hemolytic anemia due to defective glycolysis. The consequent lack of sufficient energy, which is required for normal functioning and cellular survival, shortens the life span of the mature PK-deficient erythrocyte. Consequently, PK-deficient patients display a phenotype of nonspherocytic hemolytic anemia albeit with variable clinical severity. 1 PK deficiency is transmitted as an autosomal recessive disease and to date, more than 130 mutations in PKLR have been reported to be associated with PK deficiency. 2 Most (70%) of these mutations are missense mutations affecting conserved residues in structurally and functionally important domains of PK.
The human gene for liver and red blood cell-specific PK (PKLR) is located on chromosome 1q21 3 where it directs tissuespecific transcription for both the liver-specific isozymes PK-L and the red blood cell-specific isozyme PK-R [4] [5] [6] by the use of alternate promoters. [7] [8] [9] Functional analysis of the rat PK erythroid-specific promoter has indicated that nucleotides (nts) from Ϫ870 to ϩ54, relative to the cap site, confer erythroid specificity to a reporter gene. 10 Within this region, a minimal promoter (nts Ϫ62 to ϩ54), including a putative Ϫ50 CCACC/Sp1 element and a Ϫ20 GATA element, displayed erythroid-specific activity. 10 Studies on the human promoter have, moreover, indicated that a region from Ϫ120 to Ϫ270, relative to the translational initiation codon, functions as a powerful enhancer. 9 DNA sequence comparison between the rat and human erythroid-specific promoter of PKLR reveals 4 well-conserved elements, indicated in Figure 1 . Furthermore, 2 CAC boxes and 4 GATA motifs are present within the first 250 bp upstream region. 9 So far only one mutation in the PK-R promoter has proven to be associated with PK deficiency-a single base substitution at nt Ϫ72 (Ϫ72AϾG). The down-regulation of expression by this mutated promoter has been attributed to disruption of the consensus binding motif for GATA-1 at nts Ϫ69 to Ϫ74. 11 Previously, we reported 2 in cis mutations in a severely PK-deficient Danish patient. 12 We now report on the functional analysis of these mutations and show that the most proximal one, Ϫ83GϾC, constitutes part of a core binding motif of a novel regulatory element (PKR-RE1) in the erythroid-specific promoter of PKLR, in close proximity to a regulatory GATA-1 binding site.
reticulocytes from mature erythrocytes, in order to obtain an asrepresentative-as-possible patient-specific red cell population. 13 PK activity and activity measurements of the red blood cell age-related enzymes, glucose-6-phosphate dehydrogenase (G6PD) and hexokinase (HK), were determined according to standardized procedures. 14 
DNA sequence analysis of PKLR
The coding region of PKLR was amplified using primers as previously described. 15 Additional primers were used for part of the putative erythroidspecific promoter (GenBank accession number AB015984 D13232) and 3Ј-untranslated region (3Ј-UTR; GenBank accession number D13243). Sense primer PKRP-ESF 5Ј-AGGTTACAGAGTGGTGAAGGC-3Ј (nts Ϫ469 to Ϫ449, relative to the start codon) and antisense primer PKRP-ESR 5Ј-GCTTTCAGTGTGGGCCTGG-3Ј (nts Ϫ20 to Ϫ1) amplify a 469-bp region immediately upstream of the initiator methionine. Sense primer PKRU-F 5Ј-TCTACGTTCTCCAGCCCACAC-3Ј (nts ϩ58 to ϩ78, relative to the termination codon) and antisense primer PKRU-R 5Ј-GAGTGGGAAGGAATTTCTGGG-3Ј (nts ϩ689 to ϩ669) amplify a 669-bp region of the 3Ј-UTR. Polymerase chain reactions (PCRs) were carried out with 200 ng DNA in 50-L volumes containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.01% (wt/vol) gelatin, 0.2 mM of each deoxynucleotide triphosphate (dNTP), 0.3 M of each primer, and 2.5 U AmpliTaq Gold DNA polymerase. All reagents were obtained from Applied Biosystems (Roche Molecular Systems, Branchburg, NJ). After initial incubation for 10 minutes at 95°C, samples were subjected to 35 cycles of amplification with denaturation at 94°C for 30 seconds, annealing for 30 seconds at 64°C (60°C for exon 9 and 3Ј-UTR) and extension at 72°C for 45 seconds, followed by an elongated extension time of 10 minutes after the last cycle. Automated DNA sequence analysis was performed with the ABI Prism dRhodamine Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions. Sequencing reactions were all carried out in forward and reverse direction, and samples were analyzed on an Applied Biosystems ABI 310 Genetic Analyzer (Applied Biosystems). The PCR products were purified prior to DNA sequence analysis using the QIAquick PCR purification kit (Qiagen, Valencia, CA).
Restriction enzyme analysis
Mutations were confirmed by restriction enzyme analysis on newly amplified PCR product. The cDNA sequence (c.) 1529GϾA mutation in exon 11 was confirmed by StyI digestion as described. 15 The 2 promoter mutations, Ϫ324TϾA and Ϫ83GϾC, were confirmed by digestion of the PCR product with BstXI and BsmAI, respectively. The 469-bp PCR product from the wild-type allele, as amplified with PKRP-ESF and PKRP-ESR, contains one recognition site for BstXI that yields fragments of 206 bp and 263 bp after digestion. The Ϫ324TϾA mutation creates a second recognition sequence for this enzyme, resulting in additional fragments of 152 bp and 54 bp. The Ϫ83GϾC mutation abolishes one of 2 recognition sequences for BsmAI normally present in this PCR product. Consequently, fragments of 35 bp and 434 bp are produced after digestion of the mutant allele with BsmAI, whereas 35-bp, 357-bp, and 77-bp fragments are the result of digestion of the wild-type allele with this restriction enzyme. All enzymes were purchased from New England Biolabs, Beverly, MA.
Reverse transcription-PCR
Reverse transcription-PCR (RT-PCR) to detect the c.1529GϾA mutation was performed using the GeneAmp RNA PCR Core Kit from Applied Biosystems (Roche Molecular Systems) according to the instructions of the manufacturer. Briefly, 1.0 g of the patient's reticulocyte RNA was reverse transcribed using random hexamers as primers. After addition of 30 pmol of primers CDPK-11 (5Ј-CTCAGCCCAGCTTCTGTCTCG-3Ј, exon 11 nts 1437 to 1457) and PKr-6 (5Ј-GTGTGGGCTGGAGAACGTAGA-3Ј, exon 12 nts ϩ78 to ϩ58), the samples were subjected to 35 cycles of amplification with denaturation at 94°C for 30 seconds (5 minutes at 95°C prior to the first cycle), annealing at 58°C for 30 seconds, and extension at 72°C for 30 seconds, followed by an elongated extension time of 10 minutes after the last cycle. Total liver RNA was used as a positive control and controls without RNA as well as controls in which the reverse transcription step was omitted were included.
Allelic frequency determination
Allelic frequency of Ϫ248delT and population evidence regarding its physiologic effect were obtained by screening the DNA of 241 anonymized white control subjects and heterozygotes for the c.1529GϾA mutation, respectively, for the Ϫ248delT mutation by allele-specific oligonucleotide hybridization (ASOH). Genomic DNA (100 ng) was amplified in the region of nt Ϫ248T in the PK-R promoter by PCR. The 25-L system contained 34 mM Tris-HCl, pH 8.8, 8.3 mM NH 4 SO 4 , 1.5 mM MgCl 2 , 85 g/mL bovine serum albumin, 0.2 mM of each dNTP, 100 ng of sense (5Ј-CTCCCTGGAT-TCACTAGAGC-3Ј, nts Ϫ322 to Ϫ303) and antisense (5Ј-AGGATG-GACTTTGCTAAGT-3Ј, nts 65 to 83) primers, and 1.5 U Taq DNA polymerase. After a 5-minute denaturation step at 98°C, 30 cycles of 93°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds were performed followed by a 7-minute 72°C incubation. The 405-bp PCR product (4 L) was then spotted on Nytran SuPerCharge membranes (Schleicher and Schuell, Keene, NH). The membranes were denatured, neutralized, and UV-crosslinked prior to hybridization. The membranes were hybridized with wild-type (5Ј-AAATATCTATTCACGTG-3Ј) and mutant (5Ј-AAAAATCTATTCACGTG-3Ј) 32 P-labeled oligonucleotide probes for the Ϫ248T position of the PK-R promoter. After hybridization the membranes were washed in 6 ϫ SSC, 0.1% sodium dodecyl sulfate (SDS) at 50°C and developed with a Cyclone storage phosphor autoradiography system (Packard Instrument, Meriden, CT).
Promoter constructs and site-directed mutagenesis
The human PK promoter constructs from the patient and healthy controls were generated from a 469-bp PCR fragment comprising the upstream regulatory domain and exon 1, down to the ATG codon ( Figure 1 ). The blunt-end PCR fragment was cloned into the pCR-Blunt vector (Invitrogen, Paisley, United Kingdom) before it was excised and inserted into the MluI and XhoI sites of pGL3-Basic (Promega, Madison, WI). Site-directed mutagenesis was performed with splicing by overlap extension as described. 16 Using PK-R promoter reporter plasmid pGL3_PKRWT as the wild-type template, we generated the following mutants: pGL3_PKR91A
, pGL3_PKR79T (nt Ϫ79CϾT) and pGL3_PKR78T (nt Ϫ78CϾT). Briefly, 2 PCR products were generated that harbored the desired mutation using primers PKRP-ESF and PKRP-ESR in combination with the applicable mutant antisense primers and sense primers, respectively (primer sequences are available on request). Fragments were electrophoresed and purified from the agarose gel using the QIAquick Gel Extraction Kit (Qiagen). Subsequently, for each mutant promoter construct 12.5 L of each of both fragments obtained by the first PCR reaction were combined and subjected to a second round of amplification with primers PKRP-ESF and PKRP-ESR. Finally, the bluntend mutated PCR fragment was cloned into the pCR-Blunt vector (Invitrogen), and subcloned into the XhoI and MluI sites of the pGL3-Basic vector, as described above. All constructs were verified by DNA sequence analysis. There were 3 additional mutant promoter constructs prepared as described that harbored the Ϫ248delT polymorphism (pGL3_PKR248delT), the Ϫ324TϾA mutation (pGL3_PKR324A) and, by using the patient's DNA as a template, both the Ϫ324TϾA and Ϫ83GϾC mutations in cis (pGL3_PKR324A/83C).
Cell culture and transient DNA transfections
K562 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, 1% streptomycin, and 1% penicillin in 10% CO 2 at 37°C. Cells were transiently transfected with Lipofectamine (Life Technologies, Paisley, United Kingdom) according to the manufacturer's instructions. Briefly, 30 000 cells/cm 2 were seeded in 24-well plates 24 hours prior to transfection. The cells were transfected with 2 g reporter plasmid DNA and 100 ng RL-SV40 plasmid (Promega) that was used as internal control. After 48 hours, luciferase activity was measured with the Dual Luciferase Assay kit (Promega) and normalized to renilla luciferase activity. The promoterless pGL3-Basic Luciferase Reporter Vector (Promega) was used as a negative control.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were performed essentially as described 17 with K562 nuclear extracts, prepared according to Dignam et al. 18 Wild-type and mutant double-stranded oligonucleotide probes were obtained by annealing the following single-stranded primers: PKWT, sense 5Ј-TTCTCTTCTCTGTCTCCCTT-3Ј and antisense 5ЈAAGGGAGACA-GAGAAGAGAA-3Ј; and PKmut, sense 5Ј-TTCTCTTCTCgGTCTC-CCTT-3Ј and antisense 5Ј-AAGGGAGACcGAGAAGAGAA-3Ј, respectively. PKmut contains the Ϫ84TϾG mutation (in lower case). Competitors (excess of unlabeled probe oligonucleotide or corresponding mutant oligonucleotide) were included as described in the figure legends.
Results

Glycolytic enzyme activities
The results from the measurement of peripheral blood glycolytic enzyme activities in the patient and his parents are summarized in Table 1 . In the patient, PK activity was only just below the lower reference value, whereas the HK and G6PD values were high, indicating that the red cell population was relatively young. Consequently, we interpreted the PK activity as too low. To exclude the interference of donor cells, we isolated the low-density, reticulocyte-rich fraction of the patient by Percoll-density centrifugation. Subsequent glycolytic enzyme activity measurements in this fraction showed an even lower PK activity. In contrast, the G6PD and HK activity remained unaltered, thus underscoring the presence of PK deficiency in the patient's red blood cells. The PK activity measured in peripheral blood of the father was normal, whereas the erythrocyte PK activity of the mother was low, relative to that of G6PD and HK.
DNA sequence analysis of PKLR
By DNA sequence analysis of PKLR, the patient was found to be heterozygous for the common c.1529GϾA mutation in exon 11 ( Figure 2A ). This mutation was confirmed by StyI digestion and subsequent restriction enzyme analysis of his parents revealed that the patient had inherited this allele from his father (data not shown). Apart from heterozygosity for the well-established polymorphisms 2 c.1705AϾC, c.1738CϾT, and c.1992TϾC in exon 12, no other mutations were detected in PKLR exons and splice junctions. However, 3 previously undescribed base alterations were indentified in the PK-R promoter compared with the healthy control individual. Of these, 2 were single nucleotide substitutions of, respectively, thymine to adenine at nt Ϫ324 (Ϫ324TϾA) and guanine to cytosine at nt Ϫ83 (Ϫ83GϾC). Both mutations were confirmed in the patient by BstXI and BsmAI digestion, respectively, and also found to be present in the patient's mother, whereas they were absent in the patient's father (Figure 3 ), thereby demonstrating that both mutations were present in cis. Neither allele was detected in a healthy control population (n ϭ 100). A third sequence variation was observed around nt Ϫ248 in both the patient and his mother but not in the patient's father and the control. Its characterization, however, was hampered because of an apparent concomitant variation in the number of adenines between nts Ϫ249 and Ϫ258 in all subjects. Since the latter was likely to be a PCR artifact due to slippage of Taq DNA polymerase at this homonucleotide run, 19 we cloned this promoter fragment and characterized its DNA sequence context (see "Polymorphic deletion of thymine Ϫ248").
Polymorphic deletion of thymine ؊248
DNA sequence analysis of a number of cloned promoter fragments from the patient and the control confirmed the presence of the Ϫ324TϾA and Ϫ83GϾC mutations in cis in the patient. The third mutation in the patient constituted the deletion of thymine Ϫ248 (Ϫ248delT). Since nt Ϫ248T constitutes part of an inverted consensus binding site for GATA-1, (A/T)GATA(A/G), 20 the Ϫ248delT mutation potentially disrupts binding of GATA-1 (Figure 1) . Therefore, constructs containing the wild-type (pGL3_PKRWT) and the Ϫ248delT polymorphic allele (pGL3_PKR248delT) were transiently transfected in K562 cells to determine the effect of the Ϫ248delT mutation on promoter activity. A comparison between the 2 alleles showed a statistically significant (P Ͻ .05) increase in promoter activity upon Ϫ248delT ( Figure 4A ).
In vivo evidence regarding the functional consequences on transcriptional activity of the Ϫ248delT deletion was obtained from a study of carriers of c.1529GϾA and Ϫ248delT in trans. If the Ϫ248T mutation abolished or severely impaired transcription, such compound heterozygous patients should be PK deficient and anemic or at least have macrocytosis because of increased erythropoiesis. In a previous study, 21 several thousand DNA samples from a general population were screened for the c.1529GϾA mutation and 11 heterozygotes were detected. Among these, 4 individuals also carried the Ϫ248delT mutation. Since 37 of 37 c.1529GϾA alleles carried the wild-type promoter (data not shown), it is reasonable to assume that these individuals were compound heterozygotes for c.1529GϾA and Ϫ248delT. If the Ϫ248delT mutation prevented transcription, then the patient should be PK deficient. Enzyme activities were not available, but we compared the average hemoglobin of 3 female compound heterozygotes (12.6 g/dL), which was no different than the 12.1 g/dL of the 3 female single heterozygotes for c.1529GϾA. The male patient had a hemoglobin level of 15.2 g/dL. All had normal mean corpuscular volume (MCV) values. We infer that the Ϫ248delT mutation is a benign polymorphism and is not associated with reduced promoter activity and, consequently, with PK deficiency. Subsequent determination of the allelic frequency of this mutation was performed by screening 241 control subjects of a general white population for this mutation by allele-specific oligonucleotide hybridization. There were 206 wild-type subjects (Ϫ248T/T), 34 heterozygous subjects (Ϫ248T/delT) and one homozygous control (Ϫ248delT/ delT). Consequently, the allelic frequency for this novel polymorphism in the PK-R promoter is 0.075.
Functional characterization of nt ؊324T>A and nt ؊83G>C promoter mutations
To assess the functional consequences of the mutated PK-R promoter region, we first performed RT-PCR analysis on the patient's RNA with primers spanning exons 11 and 12 to determine the relative expression of the 2 alleles. As shown in Figure 2B , only the 1529A allele could be detected in the patient, strongly Figure 3 . Heterozygosity for 2 novel mutations in the PK-R promoter at nt ؊83 (؊83G>C) and nt ؊324 (؊324T>A) in the patient and his mother. A 469-bp fragment was amplified as described and subjected to restriction enzyme digestion. The obtained pattern for each reaction is indicated by arrows (see "Patient, materials, and methods"). Heterozygosity for both the Ϫ83GϾC mutation (BsmAI digestion) and the Ϫ324TϾA mutation (BstXI digestion) was confirmed in the patient (PAT) and also detected in his mother (M), whereas they were absent in the patient's father (F). P indicates uncut PCR product; and C, healthy control. Figure 4 . The ؊83G>C mutation in the PK-R promoter strongly down-regulates promoter activity in vitro. Luciferase reporter gene constructs containing 469 bp of the wild-type or mutated PK-R promoter were transiently transfected in K562 erythroleukemic cells. Luciferase activities were expressed relative to control pGL3-SV40 and pGL3-Basic was included as a negative (promoterless) control. (A) Constructs pGL3_PKRWT and pGL3_PKR248delT contained the wild-type or polymorphic Ϫ248delT allele, respectively. The latter mutation disrupts an inverted GATA-1 binding site (arrow) but no down-regulation of promoter strength is observed. In contrast, an increase in promoter activity was observed upon removal of thymine Ϫ248. (B) Individual and combined effects of the Ϫ83GϾC and Ϫ324TϾA missense mutations were studied using constructs that contained only the Ϫ83GϾC mutation (pGL3_PKR83C) or the Ϫ324TϾA mutation (pGL3_PKR324A), or both mutations in cis (pGL3_PKR324A/83C). The Ϫ324TϾA mutation had no effect on promoter activity as compared with the wild-type (pGL3_PKRWT). In contrast, the Ϫ83GϾC mutation is capable of strongly reducing in vitro promoter activity and is unaffected by the concomitant presence of the Ϫ324TϾA substitution in cis. * Statistically significant (P Ͻ .05).
indicating that transcription is severely reduced by the mutated promoter.
To study the individual and combined effects of the Ϫ324TϾA and Ϫ83GϾC mutations on PK-R promoter activity, we transfected constructs pGL3_PKRWT (wild-type), pGL3_PKR324A (nt Ϫ324TϾA), pGL3_PKR83C (nt Ϫ83GϾC), and pGL3_PKR324A/ 83C (nt Ϫ324TϾA and nt Ϫ83GϾC in cis) in K562 cells and compared their relative luciferase activities. Figure 4B shows that the Ϫ83GϾC substitution is capable of down-regulating promoter activity (pGL3_PKR83C and pGL3_PKR324A/83C). This effect was achieved either with (pGL3_PKR324A/83C) or without (pGL3_PKR83C) the concomitant presence of the Ϫ324TϾA mutation. In contrast, promoter activity was not altered, with regard to the wild-type promoter, in case only the Ϫ324TϾA mutation was present (pGL3_PKR324A). We infer that the Ϫ83GϾC mutation disrupts transcription.
Delineation of a putative regulatory element comprising the nt ؊83G>C mutation
Since the proximal erythroid-specific promoter region of PKLR previously was reported to dictate basal promoter activity, 9 we hypothesized nt Ϫ83 to be part of a previously unrecognized trans-acting factor binding element. To unravel the sequence of the putative cis-element we generated a series of consecutive promoter mutants from nts Ϫ91 to Ϫ78 and determined their activity in K562 cells. Figure 5 shows that substitution of nts Ϫ87 to Ϫ83 leads to a decreased promoter activity. In particular, the Ϫ84TϾG mutation exhibited a profound reduction in transcription. Substitutions further upstream (nts Ϫ88 to Ϫ91) or downstream (nts Ϫ82 to Ϫ78) did not significantly alter promoter activity. Thus, we defined the existence of a novel regulatory element in the PK-R promoter PKR-RE1 whose core binding motif is confined to nts Ϫ87 to Ϫ83.
To further explore the involvement of PKR-RE1 in binding trans-acting factors, we performed EMSA with K562 nuclear extract and oligonucleotide probes designed according to the native core binding motif (PKWT) and mutated PKR-RE1 (PKmut; Ϫ84TϾG). Figure 6 demonstrates the formation of 3 distinct DNA-protein complexes upon incubation with labeled PKWT (lane 1). One of these bands (arrow) could be competed off successfully by increasing amounts of excess unlabeled PKWT (lanes 2-4), but remained unaffected by the addition of increasing amounts of excess unlabeled PKmut as a competitor (lanes 5-7), thereby establishing its specificity. This band was absent when lysates were incubated with radiolabeled PKmut (lane 8), thereby suggesting that the particular protein-DNA interaction was abolished in case PKR-RE1 was disrupted. Instead, another band appeared that could, however, be competed off successfully by increasing amounts of both unlabeled PKWT and PKmut (lanes 9-11 and 12-14, respectively). We infer that the Ϫ83C is part of a putative trans-acting factor binding element, characterized by a CTCTG core motif.
Discussion
We established the molecular basis for PK deficiency in a 6-year-old boy of Danish ancestry who suffered from severe hemolytic anemia. On the paternal allele of this patient we detected a guanine-to-adenine substitution at nt 1529 in PKLR. The Arg510Gln encoded by this frequently occurring mutation and the consequent structural changes in PK that lead to PK deficiency have been well documented. 15, 22 The fact that the father had normal PK activity (Table 1) , in spite of being heterozygous, emphasizes the difficulty of accurately identifying heterozygotes based on Figure 5 . Site-directed mutagenesis of a region of the PK-R promoter spanning nts ؊91 to ؊78 identifies the core motif CTCTG of a novel PK-R regulatory element (PKR-RE1). PK-R promoter reporter gene constructs harboring mutations from nts Ϫ91 to Ϫ78 were expressed in K562 cells. The applicable mutation is depicted in the lower part of the figure. Luciferase activities were calculated relative to control pGL3-SV40. pGL3-Basic was included as a negative (promoterless) control. The decreased promoter activity as a result of the introduced mutations at nts Ϫ87 to Ϫ83 revealed a single pentanucleotide motif CTCTG. * Statistically significant (P Ͻ .05). . PKR-RE1 is involved in DNA-protein interaction. Electrophoretic mobility shift assay was performed with K562 nuclear extract and oligonucleotide probes designed according to the native core binding motif (PKWT; lanes 1-7) and mutated PKR-RE1 (PKmut; lanes [8] [9] [10] [11] [12] [13] [14] . Absence (Ϫ) and increasing amounts of unlabeled wild-type and mutant competitor are indicated. The figure shows 3 distinct DNA-protein complexes upon incubation with labeled PKWT (lane 1). One of these bands (arrow) could be competed off successfully by increasing amounts of excess unlabeled PKWT (lanes 2-4), but remained unaffected by the addition of increasing amounts of excess unlabeled PKmut as a competitor (lanes 5-7). In contrast, this band was absent when lysates were incubated with radiolabeled PKmut (lane 8), whereas the extra band that appeared upon incubation with PKmut could be competed off succesfully by increasing amounts of both unlabeled PKWT and PKmut (lanes 9-11 and 12-14, respectively).
enzyme activity alone. On the maternal allele of the patient, we detected 3 novel mutations in the erythroid-specific promoter of PKLR. Two of these mutations were single-base substitutions, Ϫ324TϾA and Ϫ83GϾC, relative to the initiator adenine. The third change consisted of the deletion of thymine at nt Ϫ248.
RT-PCR analysis of the patient's RNA demonstrated sole expression of the 1529A allele ( Figure 2B ). Therefore, it was conceivable that the mutated promoter caused effective downregulation of transcription from the affected allele. Analysis of the various promoter mutations in K562 cells showed that Ϫ83GϾC alone was capable of inducing a drastically reduced promoter activity in vitro, whereas the Ϫ324TϾA and Ϫ248delT mutations exerted no such effect (Figure 4) . The latter mutation represents a nonfunctional polymorphic substitution (allele frequency 0.075), whereas Ϫ324TϾA is a nonfunctional mutation.
In vivo evidence regarding the lack of functional consequences on transcriptional activity of the Ϫ248delT deletion came from a study among individuals who were compound heterozygous for the c.1529GϾA and Ϫ248delT in trans. If transcription was hampered by the Ϫ248delT mutation, such patients should be PK deficient and anemic or at least have macrocytosis because of increased erythropoiesis. However, the average hemoglobin level of 3 female compound heterozygotes (12.6 g/dL) showed no differences when compared with the average hemoglobin level of 3 female single heterozygotes for c.1529GϾA (12.1 g/dL). One male patient had a hemoglobin level of 15.2 g/dL and all individuals had normal MCV values.
Because Ϫ248delT disrupts the GATA-1 binding motif at nts Ϫ244 to Ϫ249, we also investigated whether this mutation was able to influence promoter activity in vitro. Luciferase activities reflecting the relative promoter strength of these constructs showed no decline in promoter activity as a result of Ϫ248delT ( Figure  4A ). As this would have been suggestive of a functional stimulatory GATA-1 binding site in vitro, it is unlikely that the latter is the case. Thus, both in vitro and in vivo evidence support the presence of a nonfunctional GATA-1 binding site at nts Ϫ244 to Ϫ249 in the erythroid-specific promoter of PKLR. Interestingly, we found that the wild-type allele conferred an approximately 2-fold increase in promoter activity upon deletion of thymine Ϫ248 ( Figure 4A ). Although the effect is relatively small, it is possible that Ϫ248delT modulates the phenotypic expression of PK deficiency, as previously shown for a polymorphic dinucleotide repeat at the UDPglucuronosyltransferase 1 promoter 23 that contributes to the clinical phenotype in G6PD-deficient neonates. 24 Only one mutation in PKLR is known to date that is associated with a reduced transcription from its erythroid-specific promoter and consequent quantitative reduction in PK-R. A markedly reduced amount of PK-R mRNA was detected, 20% by semiquantitative RT-PCR analysis, as a result of a single nucleotide substitution at nt Ϫ72. 11 The involvement of GATA-1 was presumed since the mutation was located in the core of the binding motif of this erythroid-specific transcription factor. 20, 25, 26 Initially, a Ϫ249delA mutation in the PK-R promoter was reported in association with PK deficiency. 27 However, reinvestigation of the patient's DNA revealed the presence of the same 3 in cis mutations we report here. 27 Kugler has allowed us to examine a DNA sample from his patient, and we have confirmed his results (data not shown).
Most current data on the function of the PKLR gene indicate that the proximal promotor region is essential for transcriptional initiation. The distal region upstream position Ϫ300, where nt Ϫ324T is located, appears to be dispensable for transcriptional regulation as shown by Kanno et al, who found that removal of nts
